Brief: CytRx launches discovery laboratory to develop albumin-binding anti-cancer drug platform
13/10/2014 11:00
Oct 13 (Reuters) - CytRx Corp CYTR.O : * Says launches discovery laboratory to develop albumin-binding anti-cancer drug platform * Says discovery laboratory expected to yield first clinical candidate in 2015 * Source text for Eikon ID:nPn8RkHNZ * Further company coverage CYTR.O ((Bangalore Newsroom; +1 646 223 8780))
Recent news on LadRx
See all newsBrief: Ladrx Issues 2024 Update To Shareholders
Brief: LadRx Completes Non-Dilutive Financing Transaction For Up To $11 Mln With Xoma Corporation
Brief: LadRx Intends To Apply To List Stock On Nasdaq Under Symbol 'LADX'
Brief: LadRx Announces Review Of Strategic Alternatives, Provides Corporate Updates
Brief: CytRx Highlights Orphazyme's Update On Productive Meeting With FDA Regarding Arimoclomol In Niemann-Pick Disease Type C